This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Based in New Haven, CT, Alexion Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of life-transforming drugs, for the treatment of patients with ultra-rare disorders. The company’s complement franchise consists of key growth driver, Soliris, which is approved for the treatment of two severe and ultra-rare disorders resulting from chronic uncontrolled activation of the complement component of the immune system — paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Soliris is also approved for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. The FDA also approved its long-acting C5 complement inhibitor, Ultomiris, for the treatment of adult patients with PNH, to be administered every eight weeks. In October 2019, the FDA approved the use of Ultomiris as a treatment for adult and pediatric (one month of age or older) patients with aHUS to inhibit complement-mediated TMA.
What's in Store for IDEXX Laboratories' (IDXX) Q4 Earnings?
by Zacks Equity Research
IDEXX's (IDXX) is likely to report strong earnings for Q4, courtesy of a global surge in CAG Diagnostic revenues.
4 Top-Ranked Stocks Poised to Beat on Q4 Earnings Next Week
by Nalak Das
For fourth-quarter 2019, earnings trends are improving as companies are coming up with their reports.
Alexion Pharmaceuticals (ALXN) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Alexion (ALXN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Align Technology's (ALGN) Q4 Earnings?
by Zacks Equity Research
Align Technology (ALGN) is expected to have gained from continued adoption of Invisalign system in Q4.
New Strong Buy Stocks for January 23rd
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for today:
3 Reasons Why Alexion (ALXN) Is a Great Growth Stock
by Zacks Equity Research
Alexion (ALXN) could produce exceptional returns because of its solid growth attributes.
ALXN vs. QGEN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ALXN vs. QGEN: Which Stock Is the Better Value Option?
5 Big Drug/Biotech Stocks Set to Trump Q4 Earnings Estimates
by Zacks Equity Research
Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the fourth quarter.
Top Ranked Growth Stocks to Buy for January 22nd
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, January 22nd.
Mersana Therapeutics (MRSN) Looks Good: Stock Adds 5.8% in Session
by Zacks Equity Research
Mersana Therapeutics (MRSN) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
New Strong Buy Stocks for January 20th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today.
Top Ranked Growth Stocks to Buy for January 20th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, January 20th
Alexion to Start Pivotal Study on Ultomiris for ALS in Q1
by Zacks Equity Research
Alexion (ALXN) plans to initiate a phase III study on Ultomiris (ravulizumab) to treat amyotrophic lateral sclerosis.
Momenta (MNTA) Provides Pipeline Updates, Stock Rallies
by Zacks Equity Research
Shares of Momenta (MNTA) rise 23.7% on pipeline updates.
Alexion Pharmaceuticals (ALXN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Alexion Pharmaceuticals (ALXN) closed at $112.79 in the latest trading session, marking a -0.99% move from the prior day.
Ultragenyx Provides Preliminary Crysvita 2019 Revenues
by Zacks Equity Research
Ultragenyx (RARE) provides preliminary 2019 revenue numbers and 2020 outlook for Crysvita, along with other pipeline updates.
Alnylam Provides Preliminary Q4 Sales for Onpattro & Givlaari
by Zacks Equity Research
Alnylam (ALNY) announces preliminary results for the fourth quarter and 2019 and provides other updates.
Ultragenyx's Gene Therapy Positive in Genetic Disorder Study
by Zacks Equity Research
Shares of Ultragenyx (RARE) rise 23.4% after releasing positive top-line data from the phase I/II study of its gene therapy candidate DTX301 for the treatment of OTC deficiency.
New Strong Buy Stocks for January 13th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for today:
Top Ranked Growth Stocks to Buy for January 13th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, January 13th.
Gilead (GILD) Inks License Deal with Xencor for HIV Candidate
by Zacks Equity Research
Gilead Sciences (GILD) entered into a technology license agreement with Xencor for use of XmAb antibody technologies in investigational agents for HIV.
Has Alexion Pharmaceuticals (ALXN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (ALXN) Outperforming Other Medical Stocks This Year?
The Zacks Analyst Blog Highlights: H&R Block, Berry Global Group, Emergent BioSolutions, Pilgrim's Pride and Alexion Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: H&R Block, Berry Global Group, Emergent BioSolutions, Pilgrim's Pride and Alexion Pharmaceuticals
Incyte's Application for Pemigatinib Gets EMA's Validation
by Zacks Equity Research
The EMA endorses Incyte's (INCY) MAA for pemigatinib to treat locally advanced/metastatic cholangiocarcinoma with a FGFR2 fusion that is relapsed or refractory post minimum one line of systemic therapy.
Amarin Posts '19 Preliminary Results, Gives 2020 Expense View
by Zacks Equity Research
Amarin's (AMRN) Vascepa sales witness strong growth. The trend is anticipated to continue in 2020. However, the operating expense guidance for 2020 was higher than expected, which probably pulled the stock down.